Literature DB >> 8879356

Complications of disease and therapy: a comparison of younger and older patients with Parkinson's disease.

M L Wagner1, M N Fedak, J I Sage, M H Mark.   

Abstract

The incidence of complications associated with disease and treatment was compared in younger versus elderly patients with Parkinson's disease (PD). One hundred sixty-five patient records were divided according to patient age into two groups ("younger," 41 to 64, and "elderly," > or = 65 years) and reviewed for the incidence of dyskinesias, fluctuations, freezing, psychosis, dementia, depression, and insomnia. Younger patients had a greater incidence of chorea (75.8 percent vs 49.5 percent), dystonia (82.3 percent vs 49.0 percent), fluctuations (90.1 percent vs 68.1 percent), depression (73.2 percent vs 36.8 percent), and insomnia (57.9 percent vs 18.1 percent). There were no significant differences in the incidence of freezing, dementia, or psychosis. At the time of the first adverse event, there was no difference in patient characteristics such as gender, lag time from disease diagnosis to levodopa initiation, disease symptoms at the time of diagnosis, levodopa dose, or concomitant drug use despite the fact that the older group had a longer duration of disease, higher Hoehn and Yahr stage, an older age at onset of PD, and longer duration of levodopa use. Younger patients with PD experience a greater incidence of adverse effects than do elderly PD patients. The spectrum of adverse effects is comparable to those of young-onset (< or = 40 years) patients.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8879356

Source DB:  PubMed          Journal:  Ann Clin Lab Sci        ISSN: 0091-7370            Impact factor:   1.256


  10 in total

1.  Treatment of Depression in the Patient with Parkinson's Disease.

Authors:  Tiffany W Chow; Jeffrey L Cummings
Journal:  Clin Geriatr       Date:  1998-10

Review 2.  Depression in Parkinson's disease. Pharmacological characteristics and treatment.

Authors:  T Tom; J L Cummings
Journal:  Drugs Aging       Date:  1998-01       Impact factor: 3.923

Review 3.  Molecular pathways in dystonia.

Authors:  D Cristopher Bragg; Ioanna A Armata; Flavia C Nery; Xandra O Breakefield; Nutan Sharma
Journal:  Neurobiol Dis       Date:  2010-12-04       Impact factor: 5.996

4.  What clinical features are most useful to distinguish definite multiple system atrophy from Parkinson's disease?

Authors:  G K Wenning; Y Ben-Shlomo; A Hughes; S E Daniel; A Lees; N P Quinn
Journal:  J Neurol Neurosurg Psychiatry       Date:  2000-04       Impact factor: 10.154

Review 5.  Excessive daytime sleepiness in patients with Parkinson's disease.

Authors:  Bettina Knie; M Tanya Mitra; Kartik Logishetty; K Ray Chaudhuri
Journal:  CNS Drugs       Date:  2011-03       Impact factor: 5.749

6.  Association between new-onset Parkinson's disease and suicide risk in South Korea: a nationwide cohort study.

Authors:  Sung Hoon Jeong; Seung Hoon Kim; Doo Woong Lee; Eun-Cheol Park; Suk-Yong Jang
Journal:  BMC Psychiatry       Date:  2022-05-17       Impact factor: 4.144

7.  Efficacy of Rotigotine at Different Stages of Parkinson's Disease Symptom Severity and Disability: A Post Hoc Analysis According to Baseline Hoehn and Yahr Stage.

Authors:  Nir Giladi; Anthony P Nicholas; Mahnaz Asgharnejad; Elisabeth Dohin; Franz Woltering; Lars Bauer; Werner Poewe
Journal:  J Parkinsons Dis       Date:  2016-10-19       Impact factor: 5.568

8.  Cause or effect: Altered brain and network activity in cervical dystonia is partially normalized by botulinum toxin treatment.

Authors:  Stefan Brodoehl; Franziska Wagner; Tino Prell; Carsten Klingner; O W Witte; Albrecht Günther
Journal:  Neuroimage Clin       Date:  2019-03-26       Impact factor: 4.881

9.  Predictors of Levo-dopa induced Dyskinesias in Parkinson's Disease.

Authors:  R T Athulya; S Jayakrishnan; Thomas Iype; Reeja Rajan; Paul J Alapatt
Journal:  Ann Indian Acad Neurol       Date:  2020 Jan-Feb       Impact factor: 1.383

10.  Suicide in Parkinson's Disease.

Authors:  Wei Li; Masoom M Abbas; Sanchalika Acharyya; Hwee Lan Ng; Kay Yaw Tay; Wing Lok Au; Louis C S Tan
Journal:  Mov Disord Clin Pract       Date:  2018-03-02
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.